Diabetic foot ulcers
Diabetic foot ulcers (DFUs) are a leading cause of non-traumatic lower-limb amputation: chronic wounds in which Staphylococcus aureus and Pseudomonas aeruginosa dominate, frequently as antibiotic-tolerant, polymicrobial biofilms that systemic antibiotics penetrate poorly. Rising MRSA and multidrug-resistant Pseudomonas, plus impaired perfusion and immune function in diabetes, make many of these infections refractory to standard care and drive progression to osteomyelitis. Bacteriophages are a strong fit because they are applied topically at the wound, self-amplify on their bacterial host, carry depolymerases that degrade biofilm matrix, and kill in a strain-specific way that spares commensal flora and wound-healing tissue. A multi-phage cocktail can cover both S. aureus and P. aeruginosa simultaneously and suppress the emergence of phage-resistant mutants.
How phages act here
Mechanism
Lytic phages bind species- and strain-specific surface receptors, inject their genome, hijack the bacterium, and lyse it, releasing progeny that propagate the kill through the wound bed. For S. aureus, broad-host-range Kayvirus/Silviavirus (Myoviridae-type) phages are favored because they combine wide coverage of clinical isolates with strong biofilm-disrupting activity; anti-Pseudomonas phages contribute depolymerases that strip exopolysaccharide and expose embedded cells. Cocktails (e.g., TP-102's five phages spanning S. aureus, P. aeruginosa, and A. baumannii) broaden coverage and raise the genetic barrier to resistance versus single phages. Phage-antibiotic synergy is an active mechanism — sub-lethal antibiotics can sensitize biofilm bacteria to phage and vice versa — though it is not universal (one study found no synergy with linezolid). Engineered and CRISPR-armed phages are an emerging angle for re-sensitizing resistant strains, but for DFUs the clinical-stage work to date uses natural lytic phages.
Where it stands
Current evidence
As of 2026 the evidence is early-clinical and encouraging but not yet pivotal. BiomX's BX211 (anti-S. aureus phage) hit positive topline results in the DANCE Phase 2 randomized, double-blind, placebo-controlled trial in diabetic foot osteomyelitis (41 patients, 2:1; reported March 2025 and presented at IDWeek/Open Forum Infectious Diseases 2026): statistically significant percentage-area reduction of ulcer size versus placebo (p=0.046 at week 12; >40% separation by week 10) plus improvement in ulcer depth, with a Phase 2/3 planned pending FDA feedback. Technophage's TP-102 five-phage cocktail (targeting S. aureus, P. aeruginosa, A. baumannii) completed the Phase 1/2a REVERSE trial (NCT04803708, n=20, completed 2022; published in Med, 2025) showing it was well tolerated and safe with signals of microbial reduction/wound closure, and completed a larger Phase 2b (NCT05948592, n=76). Beyond these, the field rests on compassionate-use case series and a 2025 systematic review; no phage product is yet licensed for DFU.
Evidence confidence: medium
The data
Key studies & trials
- Nir-Paz R, Onallah H, Dekel M, Gellman YN, Haze A, Ben-Ami R, et al. Randomized double-blind study on safety and tolerability of TP-102 phage cocktail in patients with infected and non-infected diabetic foot ulcers. Med (N Y). 2025 May 9;6:100565. doi:10.1016/j.medj.2024.11.018. PMID: 39740667. ↗
- Plumet L, Magnan C, Costechareyre D, Sotto A, Lavigne J-P, Molle V. Phage therapy: a promising approach for Staphylococcus aureus diabetic foot infections. J Virol. 2025 Jun 17;99(6):e0045825. doi:10.1128/jvi.00458-25. PMID: 40366171. ↗
- Esfandiari AH, Mobarezi Z, Abolbashari S, Meshkat Z. Efficacy of phage therapy in Diabetic Foot Ulcers (DFUs): a systematic review. BMC Infect Dis. 2025 Jul 1;25:819. doi:10.1186/s12879-025-11258-x. PMID: 40596887. ↗
- BiomX Inc. Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers (REVERSE), Phase 1/2a. ClinicalTrials.gov Identifier NCT04803708 (Technophage SA; completed 2022). [BX211 DANCE Phase 2 abstract: Open Forum Infect Dis. 2026; doi:10.1093/ofid/ofaf695.086]. ↗
Who is working on it
Programs & centers
The possibility
Within a few years, a podiatrist could swab a stubborn ulcer, get a same-week phage-susceptibility match, and dress the wound with a tailored S. aureus/P. aeruginosa cocktail that self-amplifies, dissolves biofilm, and spares the patient's microbiome and remaining tissue — turning a limb-threatening infection into an outpatient regimen. Paired with debridement and short antibiotic courses to exploit phage-antibiotic synergy, this could meaningfully cut the amputations that follow drug-resistant DFUs. With two sponsors already through Phase 2 and adaptive, personalized trial designs maturing, phage therapy is among the most credible near-term routes to a licensed biologic for chronic diabetic wounds.